Molecular signature of pancreatic adenocarcinoma: An insight from genotype to phenotype and challenges for targeted therapy Review uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Agents
  • Pancreatic Neoplasms

abstract

  • Targeted therapies inhibiting pro-survival pathways have limited impact on pancreatic cancer outcomes. Activation of pro-apoptotic pathways along with suppression of cancer-stem-related pathways may reverse treatment resistance in pancreatic cancer. While targeted therapy or a 'precision medicine' approach in pancreatic adenocarcinoma remains an elusive challenge for the majority of patients, there is a real sense of optimism that the strides made in understanding the molecular underpinnings of this disease will translate into improved outcomes.

publication date

  • March 3, 2016

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4985526

Digital Object Identifier (DOI)

  • 10.1517/14728222.2016.1094057

PubMed ID

  • 26439702

Additional Document Info

start page

  • 341

end page

  • 59

volume

  • 20

number

  • 3